Histone Demethylation and Toll-like Receptor 8-Dependent Cross-Talk in Monocytes Promotes Transdifferentiation of Fibroblasts in Systemic Sclerosis Via Fra-2

Arthritis and Rheumatology

Volumn 68, Issue 6, 2016, Pages 1493-1504

  Ciechomska, Marzena ^a,b,c   O'Reilly, Steven ^a,d   Przyborski, Stefan ^d   Oakley, Fiona ^a   Bogunia Kubik, Katarzyna ^a   Van Laar, Jacob M ^a,e,f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c National Institute of Geriatrics   (Poland)

^d DURHAM UNIVERSITY   (United Kingdom)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; ALPHA SMOOTH MUSCLE ACTIN; APICIDIN; BLEOMYCIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; LUCIFERASE; NEUTRALIZING ANTIBODY; POLYCOMB REPRESSIVE COMPLEX 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; FOSL2 PROTEIN, HUMAN; FOSL2 PROTEIN, MOUSE; HISTONE; TIMP1 PROTEIN, HUMAN; TIMP1 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL TRANSDIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FIBROBLAST; FIBROGENESIS; GENE EXPRESSION; HISTONE DEMETHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; UPREGULATION; ANIMAL; CYTOLOGY; GENETIC EPIGENESIS; METABOLISM; METHYLATION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSDIFFERENTIATION; EPIGENESIS, GENETIC; FIBROBLASTS; FOS-RELATED ANTIGEN-2; HISTONES; HUMANS; METHYLATION; MICE; MIDDLE AGED; MONOCYTES; RECEPTOR CROSS-TALK; SCLERODERMA, SYSTEMIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TOLL-LIKE RECEPTOR 8;

EID: 84971223292     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39602     Document Type: Article

References (33)

1. Varga J, Abraham D., Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
2. O'Reilly S, Ciechomska M, Cant R, Hugle T, van Laar JM., Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012; 23: 99-107.
3. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, et al., Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005; 288: H461-8.
4. Song T, Dou C, Jia Y, Tu K, Zheng X., TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma. Oncotarget 2015; 6: 12061-79.
5. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al., Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Research Ther 2010; 12: R128.
6. Ciechomska M, Huigens CA, Hugle T, Stanly T, Gessner A, Griffiths B, et al., Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors. Ann Rheum Dis 2013; 72: 1382-9.
7. Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, et al., Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med 2011; 184: 569-81.
8. Ren Y, Yang H, Zhu P, Fan CM, Wang YH, Li J, et al., Effect of CsA bleomycin-induced interstitial pulmonary disease in mice. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012; 28: 232-6. In Chinese.
9. Smart DE, Vincent KJ, Arthur MJ, Eickelberg O, Castellazzi M, Mann J, et al., JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells. J Biol Chem 2001; 276: 24414-21.
10. Bahr MJ, Vincent KJ, Arthur MJ, Fowler AV, Smart DE, Wright MC, et al., Control of the tissue inhibitor of metalloproteinases-1 promoter in culture-activated rat hepatic stellate cells: regulation by activator protein-1 DNA binding proteins. Hepatology 1999; 29: 839-48.
11. Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, et al., Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2012; 64: 1642-52.
12. Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, et al., Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012; 71: 1382-7.
13. Karreth F, Hoebertz A, Scheuch H, Eferl R, Wagner EF., The AP1 transcription factor Fra2 is required for efficient cartilage development. Development 2004; 131: 5717-25.
14. Kramer M, Dees C, Huang J, Schlottmann I, Palumbo-Zerr K, Zerr P, et al., Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 2013; 72: 61420.
15. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, et al., MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138: 705-14, 714.e1-4.
16. Girard N, Bazille C, Lhuissier E, Benateau H, Llombart-Bosch A, Boumediene K, et al., 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells. PloS One 2014; 9: e98176.
17. Huber LC, Distler JH, Moritz F, Hemmatazad H, Hauser T, Michel BA, et al., Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007; 56: 2755-64.
18. Hemmatazad H, Rodrigues HM, Maurer B, Brentano F, Pileckyte M, Distler JH, et al., Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum 2009; 60: 1519-29.
19. Li M, Riddle SR, Frid MG, El Kasmi KC, McKinsey TA, Sokol RJ, et al., Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol 2011; 187: 2711-22.
20. Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, et al., CCR2 promotes hepatic fibrosis in mice. Hepatology 2009; 50: 185-97.
21. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al., Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
22. Normand J, Karasek MA., A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin. In Vitro Cell Dev Biol Anim 1995; 31: 447-55.
23. Strange G, Nash P., The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. Int J Rheumatic Dis 2009; 12: 192-206.
24. Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, et al., The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010; 62: 280-90.
25. Beyer C, Schett G, Distler O, Distler JH., Animal models of systemic sclerosis: prospects and limitations [review]. Arthritis Rheum 2010; 62: 2831-44.
26. Rajasekaran S, Vaz M, Reddy SP., Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo. PloS One 2012; 7: e41611.
27. Takada Y, Gresh L, Bozec A, Ikeda E, Kamiya K, Watanabe M, et al., Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1. Oncogene 2011; 30: 3821-32.
28. Kireva T, Erhardt A, Tiegs G, Tilg H, Denk H, Haybaeck J, et al., Transcription factor Fra-1 induces cholangitis and liver fibrosis. Hepatology 2011; 53: 1259-69.
29. Williams SM, Golden-Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos-Davies K, et al., Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 2014; 67: 112-25.
30. Binai N, O'Reilly S, Griffiths B, van Laar JM, Hugle T., Differentiation potential of CD14+ monocytes into myofibroblasts in patients with systemic sclerosis. PLoS One 2012; 7: e33508.
31. Yoo KH, Hennighausen L., EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 2012; 8: 59-65.
32. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al., EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100: 11606-11.
33. Ciechomska M, van Laar JM, O'Reilly S., Emerging role of epigenetics in systemic sclerosis pathogenesis. Genes Immun 2014; 15: 433-9.